Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P040021/S063

Epic Plus, Epic Plus Supra, Epic Max, Epic Elite, Epic Supra G3 Tissue Heart Valves

ABBOTT MEDICAL · Decision date Sep 18, 2026

MEDTECHLEDGER EXPLANATIONP040021/S063

What did the FDA decide?

FDA's decision OK30 dated 2026-09-18 covers P040021/S063, a 30-Day Notice from Abbott Medical described under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The listed products are the Epic Plus, Epic Plus Supra, Epic Max, Epic Elite and Epic Supra G3 tissue heart valves, with product code LWR. The supplement number establishes a link to PMA P040021, but this action is a manufacturing supplement to that PMA, not an approval of a new device or of the whole valve system.

The reported change has two parts: removal of the destructive pinch inspection at receiving, applicable only to Epic Elite and Epic Supra G3, and addition of a non-destructive stent pinch inspection as a 100% in-process control for all Epic valves. The source does not give inspection methods, acceptance criteria, or data on safety or clinical performance, so the notice's stated purpose should not be read as independent evidence of either.

FDA approval order statement

removal of the destructive pinch inspection at receiving (applicable to Epic Elite and Epic Supra G3 only) and the addition of a new non-destructive stent pinch inspection as a 100% in-process control for all Epic valves
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Sep 18, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P040021/S063
Regulatory pathway
PMA supplement
Product code
LWR
Decision code
OK30
Decision date
Sep 18, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: heart-valve, non-allograft tissue.

Product code
LWR
FDA device class
3

For the original device and its historical approval scope, see PMA P040021. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P040021 · Original PMA

    SJM BIOCOR VALVE / SJM BIOCOR SUPRA VALVE

  2. P040021/S063 received

    Application receipt date recorded by FDA.

  3. P040021/S063 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P040021. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P040021

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT MEDICALPMA approvalAug 5, 2005FDA

Explore the linked device profile

Other records with product code LWR

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
177 County Rd. B E., St. Paul, MN, 55117

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records